$ISCO
International Stem Cell CORP Stock $isco

$isco Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024038092 Filed on March 28, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$2.129M	$1.889M	$7.789M
YoY Change	2.06%	-22.26%	-4.78%
Cost Of Revenue	$887.0K	$863.0K	$3.181M
YoY Change	7.65%	-24.03%	-2.69%
Gross Profit	$1.242M	$1.026M	$4.608M
YoY Change	-1.58%	-20.71%	-6.17%
Gross Profit Margin	58.34%	54.31%	59.16%
Selling, General & Admin	$1.243M	$1.284M	$4.760M
YoY Change	11.48%	15.88%	3.43%
% of Gross Profit	100.08%	125.15%	103.3%
Research & Development	$177.0K	$166.0K	$511.0K
YoY Change	22.07%	32.8%	3.86%
% of Gross Profit	14.25%	16.18%	11.09%
Depreciation & Amortization	$49.00K	$48.00K	$194.0K
YoY Change	-3.92%	-7.69%	-11.01%
% of Gross Profit	3.95%	4.68%	4.21%
Operating Expenses	$1.420M	$1.450M	$5.271M
YoY Change	12.7%	17.6%	3.47%
Operating Profit	-$178.0K	-$424.0K	-$663.0K
YoY Change	-9000.0%	-795.08%	262.3%
Interest Expense	$36.00K	-$34.00K	$139.0K
YoY Change	0.0%	3.03%	2.96%
% of Operating Profit
Other Income/Expense, Net	-$36.00K	$0.00	$532.0K
YoY Change	0.0%	-100.0%	-459.46%
Pretax Income	-$214.0K	-$458.0K	-$131.0K
YoY Change	529.41%	-2091.3%	-60.42%
Income Tax
% Of Pretax Income
Net Earnings	-$214.0K	-$303.0K	-$131.0K
YoY Change	529.41%	-1417.39%	-60.42%
Net Earnings / Revenue	-10.05%	-16.04%	-1.68%
Basic Earnings Per Share	-$0.03		-$0.02
Diluted Earnings Per Share	-$0.03	-$0.04	-$0.02
COMMON SHARES
Basic Shares Outstanding	8.004M	8.004M	8.004M
Diluted Shares Outstanding	8.004M		8.004M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.386M	$1.588M	$1.588M
YoY Change	46.98%	114.02%	114.02%
Cash & Equivalents	$1.386M	$1.588M
Short-Term Investments
Other Short-Term Assets	$32.00K	$96.00K	$96.00K
YoY Change	23.08%	6.67%	6.67%
Inventory	$1.273M	$1.263M	$1.263M
Prepaid Expenses	$270.0K	$80.00K
Receivables	$632.0K	$574.0K	$574.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$3.593M	$3.521M	$3.521M
YoY Change	11.03%	18.83%	18.83%
LONG-TERM ASSETS
Property, Plant & Equipment	$196.0K	$215.0K	$772.0K
YoY Change	-15.52%	-13.31%	-20.82%
Goodwill
YoY Change
Intangibles	$854.0K	$875.0K
YoY Change	-0.47%	-0.34%
Long-Term Investments
YoY Change
Other Assets	$291.0K	$297.0K	$297.0K
YoY Change	-11.28%	-6.9%	-6.9%
Total Long-Term Assets	$1.776M	$1.869M	$1.869M
YoY Change	-15.63%	-13.95%	-13.95%
TOTAL ASSETS
Total Short-Term Assets	$3.593M	$3.521M	$3.521M
Total Long-Term Assets	$1.776M	$1.869M	$1.869M
Total Assets	$5.369M	$5.390M	$5.390M
YoY Change	0.52%	4.97%	4.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$360.0K	$364.0K	$364.0K
YoY Change	2.56%	13.04%	13.04%
Accrued Expenses	$578.0K	$485.0K	$761.0K
YoY Change	-8.54%	-4.53%	3.12%
Deferred Revenue
YoY Change
Short-Term Debt	$3.490M	$3.457M	$3.457M
YoY Change	3.96%	3.97%	3.97%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.966M	$4.832M	$4.832M
YoY Change	2.79%	4.25%	4.25%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$367.0K	$445.0K	$445.0K
YoY Change	-44.05%	-38.19%	-38.19%
Total Long-Term Liabilities	$367.0K	$445.0K	$445.0K
YoY Change	-44.05%	-38.19%	-38.19%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.966M	$4.832M	$4.832M
Total Long-Term Liabilities	$367.0K	$445.0K	$445.0K
Total Liabilities	$5.333M	$5.277M	$5.277M
YoY Change	-2.81%	-1.46%	-1.46%
SHAREHOLDERS EQUITY
Retained Earnings	-$110.7M	-$110.5M
YoY Change	0.27%	0.18%
Common Stock	$8.000K	$8.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$4.264M	-$4.187M	$113.0K
YoY Change
Total Liabilities & Shareholders Equity	$5.369M	$5.390M	$5.390M
YoY Change	0.52%	4.97%	4.97%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$214.0K	-$303.0K	-$131.0K
YoY Change	529.41%	-1417.39%	-60.42%
Depreciation, Depletion And Amortization	$49.00K	$48.00K	$194.0K
YoY Change	-3.92%	-7.69%	-11.01%
Cash From Operating Activities	-$193.0K	$161.0K	$929.0K
YoY Change	-189.35%	103.8%	179.82%
INVESTING ACTIVITIES
Capital Expenditures	$8.000K	$0.00	$80.00K
YoY Change	-46.67%	-100.0%	7900.0%
Acquisitions
YoY Change
Other Investing Activities		-$3.000K	-$3.000K
YoY Change
Cash From Investing Activities	-$9.000K	-$3.000K	-$83.00K
YoY Change	-40.0%	0.0%	654.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-193.0K	161.0K	929.0K
Cash From Investing Activities	-9.000K	-3.000K	-83.00K
Cash From Financing Activities	0.000	0.000	0.000
Net Change In Cash	-202.0K	158.0K	846.0K
YoY Change	-200.5%	107.89%	48.16%
FREE CASH FLOW
Cash From Operating Activities	-$193.0K	$161.0K	$929.0K
Capital Expenditures	$8.000K	$0.00	$80.00K
Free Cash Flow	-$201.0K	$161.0K	$849.0K
YoY Change	-200.0%	111.84%	156.5%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001355790
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023Q4	us-gaap	Notes Payable Current Related Party Type Extensible Enumeration NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4	us-gaap	Notes Payable Current Related Party Type Extensible Enumeration NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2023	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	0-51891
CY2023	dei	Entity Registrant Name EntityRegistrantName	INTERNATIONAL STEM CELL CORPORATION
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-4494098
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	9745 Businesspark Ave
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92131
CY2023	dei	City Area Code CityAreaCode	760
CY2023	dei	Local Phone Number LocalPhoneNumber	940-6383
CY2023	dei	Security12g Title Security12gTitle	Common Stock, $0.001 par value per share
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	481068
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8004389
CY2023	dei	Auditor Name AuditorName	BDO USA, P.C.
CY2023	dei	Auditor Location AuditorLocation	San Diego, California
CY2023	dei	Auditor Firm AuditorFirmId	243
CY2023Q4	us-gaap	Cash Cash	1588000
CY2022Q4	us-gaap	Cash Cash	742000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	574000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	747000
CY2023Q4	us-gaap	Inventory Net InventoryNet	1263000
CY2022Q4	us-gaap	Inventory Net InventoryNet	1384000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	96000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	90000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	3521000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	2963000
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	266000
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	286000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	215000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	248000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	800000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	878000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	557000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	727000
CY2023Q4	isco	Deposits And Other Assets DepositsAndOtherAssets	31000
CY2022Q4	isco	Deposits And Other Assets DepositsAndOtherAssets	33000
CY2023Q4	us-gaap	Assets Assets	5390000
CY2022Q4	us-gaap	Assets Assets	5135000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	364000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	322000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	485000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	508000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	276000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	230000
CY2023Q4	isco	Advances From Nonaffiliated Collaboration AdvancesFromNonaffiliatedCollaboration	250000
CY2022Q4	isco	Advances From Nonaffiliated Collaboration AdvancesFromNonaffiliatedCollaboration	250000
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	3457000
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	3325000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4832000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4635000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	445000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	720000
CY2023Q4	us-gaap	Liabilities Liabilities	5277000
CY2022Q4	us-gaap	Liabilities Liabilities	5355000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8004389
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8004389
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8004389
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8004389
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	8000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	8000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	106276000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	105812000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-110476000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-110345000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-4187000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-4520000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5390000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5135000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7789000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8180000
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	3181000
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	3269000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3514000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3357000
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1246000
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1245000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	511000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	492000
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	8452000
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	8363000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-663000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-183000
CY2023	isco	Employee Retention Credit EmployeeRetentionCredit	663000
CY2023	us-gaap	Interest Expense InterestExpense	139000
CY2022	us-gaap	Interest Expense InterestExpense	135000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	8000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-13000
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	532000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-148000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-131000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-331000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8004389
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8004389
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8004389
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8004389
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-4588000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	399000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-331000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-4520000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	464000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-131000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-4187000
CY2023	us-gaap	Profit Loss ProfitLoss	-131000
CY2022	us-gaap	Profit Loss ProfitLoss	-331000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	194000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	218000
CY2023	isco	Non Cash Operating Lease Expense NonCashOperatingLeaseExpense	170000
CY2022	isco	Non Cash Operating Lease Expense NonCashOperatingLeaseExpense	141000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	464000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	399000
CY2023	isco	Interest Expense On Related Party Note Payable InterestExpenseOnRelatedPartyNotePayable	132000
CY2022	isco	Interest Expense On Related Party Note Payable InterestExpenseOnRelatedPartyNotePayable	132000
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-173000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-97000
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-141000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	114000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-45000
CY2023	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-2000
CY2022	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-6000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	42000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-186000
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-23000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	104000
CY2023	isco	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-229000
CY2022	isco	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-179000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	929000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	332000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	80000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1000
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	3000
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	10000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-83000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11000
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	250000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	250000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	846000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	571000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	742000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	171000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1588000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	742000
CY2023	us-gaap	Interest Paid Net InterestPaidNet	6000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	3000
CY2023	isco	Patent License Costs Included In Accounts Payable And Accrued Expense PatentLicenseCostsIncludedInAccountsPayableAndAccruedExpense	1000
CY2022	isco	Patent License Costs Included In Accounts Payable And Accrued Expense PatentLicenseCostsIncludedInAccountsPayableAndAccruedExpense	2000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-110500000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the accompanying consolidated financial statements. Significant estimates include patent life (remaining legal life versus remaining useful life), allowance for excess and obsolete inventories, and stock option awards using the Black-Scholes option valuation model. Actual results could differ from those estimates.</span></p>
CY2023	us-gaap	Revenue Performance Obligation Description Of Payment Terms RevenuePerformanceObligationDescriptionOfPaymentTerms	The Company's revenue consists primarily of sales of products from its two revenue-generating operating segments: the biomedical products market and anti-aging products market. The biomedical market segment markets and sells primary human cell research products with two product categories, cells and media, which are sold both domestically within the United States and internationally. The anti-aging market segment markets and sells a line of skincare products directly to customers through online orders via the ecommerce sales channel.
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2
CY2023Q4	isco	Number Of Products Categories NumberOfProductsCategories	2
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	747000
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3
CY2023	isco	Number Of Business Units NumberOfBusinessUnits	2
CY2008Q2	isco	Advances From Nonaffiliated Collaboration AdvancesFromNonaffiliatedCollaboration	250000
CY2008Q2	isco	Advances From Nonaffiliated Collaboration AdvancesFromNonaffiliatedCollaboration	250000
CY2008Q2	isco	Specified Amount Of Revenue To Be Utilized First For Advances SpecifiedAmountOfRevenueToBeUtilizedFirstForAdvances	250000
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	0
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	574000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	844000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	747000
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2023Q4	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P15Y
CY2023	isco	Product Return Guarantee Period ProductReturnGuaranteePeriod	P30D
CY2023	isco	Allowance For Sales Return AllowanceForSalesReturn	0
CY2022	isco	Allowance For Sales Return AllowanceForSalesReturn	0
CY2023	us-gaap	Advertising Expense AdvertisingExpense	204000
CY2022	us-gaap	Advertising Expense AdvertisingExpense	220000
CY2023	isco	Reduction In Research And Development Expenses ReductionInResearchAndDevelopmentExpenses	99000
CY2022	isco	Reduction In Research And Development Expenses ReductionInResearchAndDevelopmentExpenses	80000
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16109285
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12537176
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Customer Concentrations</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> customer accounted for approxim</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">46</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">45</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, of consolidated product sales, and approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">52</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">51</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, respectively, of biomedical product sales. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, the same customer accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">47</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">73</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, of accounts receivable, net.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No other single customer accounted for more than 10% of product sales, net for the years ended December 31, 2023 and 2022 in either segment. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> customers individually accounted for more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of accounts receivable, net and in the aggregate, accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">33</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of accounts receivable, net. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No other single customer accounted for more than 10% of accounts receivable, net as of December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2541000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2467000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2326000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2219000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	215000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	248000
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	112000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	137000
CY2023	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	5000
CY2022	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	41000
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	526000
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	615000
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	597000
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	498000
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1145000
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1194000
CY2023Q4	us-gaap	Inventory Gross InventoryGross	2268000
CY2022Q4	us-gaap	Inventory Gross InventoryGross	2307000
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	739000
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	637000
CY2023Q4	isco	Inventory Net Current And Noncurrent InventoryNetCurrentAndNoncurrent	1529000
CY2022Q4	isco	Inventory Net Current And Noncurrent InventoryNetCurrentAndNoncurrent	1670000
CY2023Q4	us-gaap	Inventory Net InventoryNet	1263000
CY2022Q4	us-gaap	Inventory Net InventoryNet	1384000
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	266000
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	286000
CY2023Q4	isco	Inventory Net Current And Noncurrent InventoryNetCurrentAndNoncurrent	1529000
CY2022Q4	isco	Inventory Net Current And Noncurrent InventoryNetCurrentAndNoncurrent	1670000
CY2023Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	1290000
CY2022Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	1286000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	565000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	483000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	725000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	803000
CY2023Q4	us-gaap	Indefinite Lived Trademarks IndefiniteLivedTrademarks	75000
CY2022Q4	us-gaap	Indefinite Lived Trademarks IndefiniteLivedTrademarks	75000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	800000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	878000
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	82000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	81000
CY2023Q4	isco	Finite Lived Pending Patents FiniteLivedPendingPatents	61000
CY2022Q4	isco	Finite Lived Pending Patents FiniteLivedPendingPatents	57000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	82000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	80000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	76000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	73000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	73000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	341000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	725000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023	us-gaap	Dividends Preferred Stock DividendsPreferredStock	0
CY2023	us-gaap	Preferred Stock Voting Rights PreferredStockVotingRights	The holders of Series B, Series D, and Series G are entitled to one vote for each share of common stock into which it would convert.
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	37351888
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	464000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	399000
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	650000
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y10M2D
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-76000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-228000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-55000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-103000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-131000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-331000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.680
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.085
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.413
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.008
CY2023	isco	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.092
CY2022	isco	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.051
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	118.158
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	1.907
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-12.41
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0
CY2023	isco	Effective Income Tax Rate Reconciliation Employee Retention Credit Income EffectiveIncomeTaxRateReconciliationEmployeeRetentionCreditIncome	1.045
CY2022	isco	Effective Income Tax Rate Reconciliation Employee Retention Credit Income EffectiveIncomeTaxRateReconciliationEmployeeRetentionCreditIncome	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-2.269
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.080
CY2023	isco	Effective Income Tax Rate Reconciliation Adjustment To Nol EffectiveIncomeTaxRateReconciliationAdjustmentToNol	-108.305
CY2022	isco	Effective Income Tax Rate Reconciliation Adjustment To Nol EffectiveIncomeTaxRateReconciliationAdjustmentToNol	-0.406
CY2023	isco	Effective Income Tax Rate Reconciliation Asc74010 Adjustment EffectiveIncomeTaxRateReconciliationAsc74010Adjustment	4.02
CY2022	isco	Effective Income Tax Rate Reconciliation Asc74010 Adjustment EffectiveIncomeTaxRateReconciliationAsc74010Adjustment	-1.70
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.090
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.037
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	478000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	953000
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	953000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	953000
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	475000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	478000
CY2023	isco	Net Operating Loss Carryforwards Expiration Date Description NetOperatingLossCarryforwardsExpirationDateDescription	various years beginning 2026 through 2037
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5476000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	19266000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	922000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1993000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	995000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1252000
CY2023Q4	isco	Deferred Tax Assets Irc Section174 Costs DeferredTaxAssetsIrcSection174Costs	172000
CY2022Q4	isco	Deferred Tax Assets Irc Section174 Costs DeferredTaxAssetsIrcSection174Costs	95000
CY2023Q4	isco	Deferred Tax Assets Intangible Assets DeferredTaxAssetsIntangibleAssets	166000
CY2022Q4	isco	Deferred Tax Assets Intangible Assets DeferredTaxAssetsIntangibleAssets	191000
CY2023Q4	isco	Deffered Tax Asset Lease Liabilities DefferedTaxAssetLeaseLiabilities	161000
CY2022Q4	isco	Deffered Tax Asset Lease Liabilities DefferedTaxAssetLeaseLiabilities	224000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	123000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	128000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	8015000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	23149000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	7858000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	22936000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	157000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	213000
CY2023Q4	isco	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	125000
CY2022Q4	isco	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	171000
CY2023Q4	isco	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	32000
CY2022Q4	isco	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	42000
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	157000
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	213000
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2021Q4	isco	Lease Costs Incurred Percentage LeaseCostsIncurredPercentage	0.40
CY2023	isco	Number Of Operating Leases NumberOfOperatingLeases	3
CY2021Q4	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2026-12-31
CY2021Q4	us-gaap	Operating Lease Expense OperatingLeaseExpense	11000
CY2021Q4	isco	Percentage Of Increase Rent Per Annum Over Lease Term PercentageOfIncreaseRentPerAnnumOverLeaseTerm	0.035
CY2021Q4	isco	Percentage Of Base Rent Abated PercentageOfBaseRentAbated	0.50
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	232000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	232000
CY2021Q4	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2026-12-31
CY2021Q4	us-gaap	Operating Lease Expense OperatingLeaseExpense	4000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	247000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	247000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	557000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	721000
CY2023Q4	isco	Finance Leases FinanceLeases	0
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	278
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	278
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	5
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	7
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	159
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	167
CY2023	us-gaap	Lease Cost LeaseCost	442
CY2022	us-gaap	Lease Cost LeaseCost	452
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	338
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	317
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y5M8D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y5M4D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.132
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1338
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	349000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	360000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	119000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	828000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	107000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	721000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	276000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	445000
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3
CY2023	isco	Number Of Business Units NumberOfBusinessUnits	2
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7789000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8180000
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	8452000
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	8363000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-663000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-183000
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	532000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-148000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-131000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-331000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7789000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8180000

Files In Submission

Name	View Source	Status
0000950170-24-038092-index-headers.html	Edgar Link	pending
0000950170-24-038092-index.html	Edgar Link	pending
0000950170-24-038092.txt	Edgar Link	pending
0000950170-24-038092-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
isco-20231231.htm	Edgar Link	pending
isco-20231231.xsd	Edgar Link	pending
isco-ex23_1.htm	Edgar Link	pending
isco-ex31_1.htm	Edgar Link	pending
isco-ex31_2.htm	Edgar Link	pending
isco-ex32_1.htm	Edgar Link	pending
isco-ex32_2.htm	Edgar Link	pending
isco-ex97_1.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
isco-20231231_htm.xml	Edgar Link	completed
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ISCO
International Stem Cell CORP Stock $isco

2024 Q1 Form 10-K Financial Statement

#000095017024038092 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ISCO International Stem Cell CORP Stock $isco

2024 Q1 Form 10-K Financial Statement

#000095017024038092 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ISCO
International Stem Cell CORP Stock $isco